HBsAg-negative hepatitis B virus infection and hepatocellular carcinoma

Discovery Medicine

Volumn 18, Issue 99, 2014, Pages 189-193

  Chen, Liping ^a   Zhao, Hong ^b   Yang, Xiaoqin ^a   Gao, Jackson Y ^c   Cheng, Jilin ^a  

^a FUDAN UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN;

ARTICLE; CHRONIC HEPATITIS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; HEPATITIS B; HUMAN; IMMUNITY; IMMUNOASSAY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MUTATION; NUCLEIC ACID ANALYSIS; OCCULT HEPATITIS B VIRUS INFECTION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PUBLIC HEALTH; RISK FACTOR; SEROLOGY; VIRUS GENOME; BLOOD; FEMALE; HEPATITIS B VIRUS; IMMUNOLOGY; LIVER TUMOR; MALE; METABOLISM; PATHOLOGY; VIROLOGY;

CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MALE;

EID: 84940490117     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Ahn SH, Park YN, Park JY, Chang HY, Lee JM, Shin JE, Han KH, Park C, Moon YM, Chon CY. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 42(2):188-194, 2005.
2. Bai F, Yano Y, Fukumoto T, Takebe A, Tanaka M, Kuramitsu K, Anggorowati N, Rinonce HT, Widasari DI, Saito M, Hirano H, Hayakumo T, Seo Y, Azuma T, Ku Y, Hayashi Y. Quantification of pregenomic RNA and covalently closed circular DNA in hepatitis B virus-related hepatocellular carcinoma. Int J Hepatol 2013:849290, 2013.
3. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 52(4):1232-1241, 2010.
4. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH, Group R-HS. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1):65-73, 2006.
5. Chen CY, Wu JR, Zhu XY, Wang SY. [Occult hepatitis B virus infection]. Zhonghua Gan Zang Bing Za Zhi 13(11):873-875, 2005.
6. Covolo L, Pollicino T, Raimondo G, Donato F. Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis. Dig Liver Dis 45(3):238-244, 2013.
7. Duan XY, Qiao L, Fan JG. Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 11(1):18-27, 2012.
8. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 37(Suppl 2):S88-S94, 2007.
9. Elmore LW, Hancock AR, Chang SF, Wang XW, Chang S, Callahan CP, Geller DA, Will H, Harris CC. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci U S A 94(26):14707-14712, 1997.
10. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 34(6):1329-1339, 2005.
11. Huang FY, Wong DK, Seto WK, Zhang AY, Lee CK, Lin CK, Fung J, Lai CL, Yuen MF. Sequence variations of full-length hepatitis B virus genomes in Chinese patients with HBsAg-negative hepatitis B infection. Plos One 9(6):e99028, 2014.
12. Huang YH, Hung HH, Chan CC, Lai CR, Chu CJ, Huo TI, Lee PC, Su CW, Lan KH, Huang HC, Lee IC, Lin HC, Lee SD. Core antigen expression is associated with hepatic necroinflammation in e antigen-negative chronic hepatitis B patients with low DNA loads. Clin Vaccine Immunol 17(6):1048-1053, 2010.
13. Lee KM, Kim YS, Ko YY, Yoo BM, Lee KJ, Kim JH, Hahm KB, Cho SW. Emergence of vaccine-induced escape mutant of hepatitis B virus with multiple surface gene mutations in a Korean child. J Korean Med Sci 16(3):359-362, 2001.
14. Li T, Qin LX, Gong X, Zhou J, Sun HC, Qiu SJ, Ye QH, Wang L, Fan J. Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection. Cancer 119(1):126-135, 2013.
15. Louisirirotchanakul S, Kanoksinsombat C, Theamboonlert A, Puthavatana P, Wasi C, Poovorawan Y. Mutation of the "a" determinant of HBsAg with discordant HBsAg diagnostic kits. Viral Immunol 17(3):440-444, 2004.
16. Mahmoud OA, Ghazal AA, Metwally Del S, Elnour AM, Yousif GE. Detection of occult hepatitis B virus infection among blood donors in Sudan. J Egyt Public Health Assoc 88(1):14-18, 2013.
17. Mahtab MA, Akbar SM, Rahman S. Hepatitis B surface antigen-negative, but HBV DNA-positive patients in Bangladesh. Bangladesh Med Res Counc Bull 38(3):104-107, 2012.
18. Monjezi R, Tan SW, Tey BT, Sieo CC, Tan WS. Detection of hepatitis B virus core antigen by phage display mediated TaqMan real-time immuno-PCR. J Virol Methods 187(1):121-126, 2013.
19. Ohba K, Kubo S, Tamori A, Hirohashi K, Tanaka H, Shuto T, Nishiguchi S, Kinoshita H. Previous or occult hepatitis B virus infection in hepatitis B surface antigen-negative and anti-hepatitis C-negative patients with hepatocellular carcinoma. Surg Today 34(10):842-848, 2004.
20. Okada S, Sato T, Okusaka T, Ishii H, Ikeda M, Nakasuka H, Kosakamoto H, Yoshimori M, Wakabayashi K. Past exposure to hepatitis B virus as a risk factor for hepatocellular carcinoma in patients with chronic liver disease. Br J Cancer 77(11):2028-2031, 1998.
21. Paterlini P, Driss F, Nalpas B, Pisi E, Franco D, Berthelot P, Brechot C. Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: a study of a low-endemic area. Hepatology 17(1):20-29, 1993.
22. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45(4):529-538, 2006.
23. Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, Levrero M, Raimondo G. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 45(2):277-285, 2007.
24. Pollicino T, Saitta C. Occult hepatitis B virus and hepatocellular carcinoma. World J Gastroenterol 20(20):5951-5961, 2014.
25. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 126(1):102-110, 2004.
26. Qin S, Tang H, Zhao LS, He F, Lin Y, Liu L, He XM. Cloning of HBsAg-encoded genes in different vectors and their expression in eukaryotic cells. World J Gastroenterol 9(5):1111-1113, 2003.
27. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxi A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49(4):652-657, 2008.
28. Raimondo G, Pollicino T, Romano L, Zanetti AR. A 2010 update on occult hepatitis B infection. Pathol Biol 58(4):254-257, 2010.
29. Shim J, Kim BH, Kim NH, Dong SH, Kim HJ, Chang YW, Lee JI, Chang R. Clinical features of HBsAg-negative but anti-HBc-positive hepatocellular carcinoma in a hepatitis B virus endemic area. J Gastroenterol Hepatol 20(5):746-751, 2005.
30. Tamori A, Nishiguchi S, Kubo S, Narimatsu T, Habu D, Takeda T, Hirohashi K, Shiomi S. HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan. J Med Virol 71(4):492-498, 2003.
31. Tong MJ, Nguyen MO, Tong LT, Blatt LM. Development of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen. Clin Gastroenterol Hepatol 7(8):889-893, 2009.
32. Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, Chen DS, Kao JH. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 141(2):517-525, 525.e1-2, 2011.
33. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology 55(1):68-76, 2012.
34. Uzun Y, Bozkaya H, Erden E, Cinar K, Idilman R, Yurdaydin C, Uzunalimoglu O. Hepatitis B core antigen expression pattern reflects the response to anti-viral treatment. J Gastroenterol Hepatol 21(6):977-981, 2006.
35. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WET, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126(7):1750-1758, 2004.
36. Wong DK, Huang FY, Lai CL, Poon RT, Seto WK, Fung J, Hung IF, Yuen MF. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 54(3):829-836, 2011.
37. Yano Y, Yamashita F, Sumie S, Ando E, Fukumori K, Kiyama M, Oyama T, Kuroki S, Kato O, Yamamoto H, Tanaka M, Sata M. Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antibody but positive for anti-HBc antibody in Japan. Am J Gastroenterol 97(1):156-161, 2002.
38. Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, Siu CW, Sander TJ, Bourne EJ, Hall JG, Condreay LD, Lai CL. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 39(6):1694-1701, 2004.
39. Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, Omura M, Hikiji K, Kato M. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 37(5):1172-1179, 2003.